Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Recruiting 2Completed 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Conditions

Leukemia, Myeloid, Acute 384Myelodysplastic Syndromes 160Leukemia, Myelomonocytic, Chronic 76Leukemia 65Recurrence 32Myeloproliferative Disorders 23Hematologic Neoplasms 20Neoplasms 19Multiple Myeloma 17Carcinoma, Non-Small-Cell Lung 17Lymphoma, Non-Hodgkin 16Lymphoma 16Precursor Cell Lymphoblastic Leukemia-Lymphoma 15Lymphoma, Large B-Cell, Diffuse 14Anemia, Refractory, with Excess of Blasts 14Lymphoma, T-Cell, Peripheral 13Primary Myelofibrosis 12Neoplasm, Residual 12Leukemia, Monocytic, Acute 11Leukemia, Lymphocytic, Chronic, B-Cell 11Leukemia, Biphenotypic, Acute 11Leukemia, Myelomonocytic, Acute 10Hodgkin Disease 10Myelodysplastic-Myeloproliferative Diseases 9Leukemia, Erythroblastic, Acute 9Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 8Leukemia, Myeloid 8Leukemia, Myelogenous, Chronic, BCR-ABL Positive 8Leukemia, Megakaryoblastic, Acute 8Congenital Abnormalities 8

Interventions

Azacitidine 3venetoclax 1eprenetapopt 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Myeloid Malignancy × Azacitidine × Clear all
NCT03850418 2026-02-24

Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant

Henry Ford Health System

Phase 2 Recruiting
43 enrolled

Myeloid Malignancy

NCT07011186 2025-06-08

A Clinical Trial of TQB3909 Tablets in Combination With Azacitidine for the Treatment of Myeloid Malignancies

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 1/2 Recruiting
138 enrolled

Myeloid Malignancy

NCT04214860 2025-03-17

APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies

Aprea Therapeutics

Phase 1 Completed
51 enrolled 9 charts

Myeloid Malignancy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡